Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Yuanyin Bio logo — Pioneering the future of medicine with groundbreaking RNA te...

Yuanyin Bio

Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clinical needs and develop novel preventive and therapeutic solutions.

Founded 2021 Series A Total: $142.00M Biopharma, Biotechnology +1

General Information

Company Name Yuanyin Bio
Founded Year 2021
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, Platform, B2B2C
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Yuanyin Bio. To contact Yuanyin Bio, visit therorna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Yuanyin Bio compare?

A PDF of Yuanyin Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Yuanyin Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Yuanyin Bio

Yuanyin Bio is emerging as a disruptive force in the Biopharma, Biotechnology, and Pharmaceutical sectors with its focus on circular RNA technology. Founded in 2021, the company aims to revolutionize the medical field through its commitment to creating innovative drugs and therapies.

The startup is building a robust pipeline of new drugs, targeting diseases that currently lack effective treatment options, thus addressing significant unmet clinical needs. Their vision aligns with their slogan: "Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clinical needs and develop novel preventive and therapeutic solutions."

In their recent round of funding, Yuanyin Bio secured a $42.00M Series A investment from a consortium of prominent investors including Cenova, MSA Capital, Quan Capital, 3H Health Investment, Sherpa Healthcare Partners, Tencent, and Sanzheng Health. This substantial financial backing underscores investor confidence in their potential to innovate within their industry.

Business keywords: RNA technology, circular RNA, innovative drugs, therapeutic solutions, preventive medicine, unmet clinical needs, drug development, therapeutics pipeline, novel therapies, disease treatment, medical innovation, biopharmaceuticals, clinical research, disease targeting

Services & Products

Development of new pharmaceutical products
Research and application of circular RNA technology
Creation of therapeutic and preventive medicines

Target Customers

Healthcare providers Pharmaceutical companies Medical research institutions Biotechnology developers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $42.00M 5
Cenova 3H Health Investment MSA Capital
Cenova, 3H Health Investment +3
01 May 2022
Seed CNY100.00M 2
Cenova Quan Capital
Cenova, Quan Capital
01 Nov 2021
Spinout Undisclosed 1
University Ventures
University Ventures
01 Jan 2021

Yuanyin Bio Alternatives & Competitors

View All Alternatives
Yuanyin Bio vs
Cosmo Pharmaceuticals
Cosmo Pharmaceuticals Ireland

We develop innovative treatments that address significant unmet clinical needs

Post-IPO Debt
202 employees
Biotechnology, Health Care
Yuanyin Bio vs
MediciNova
MediciNova

Focused on innovative small-molecule therapeutics, addressing unmet medical needs with strategic all...

Post-IPO Equity
Biotechnology, Health and Wellness
Yuanyin Bio vs
Aclipse Therapeutics
Aclipse Therapeutics United States

Aclipse develops novel and highly differentiated therapeutics to treat diseases with significant unm...

Grant
10 employees
Biotechnology, Pharmaceutical
Also compare with: Yuanyin Bio vs Cirius Therapeutics Cirius Therapeutics Yuanyin Bio vs Orna Therapeutics Orna Therapeutics Yuanyin Bio vs Calluna Pharma Calluna Pharma View all alternatives

FAQ About Yuanyin Bio

Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clinical needs and develop novel preventive and therapeutic solutions.
Yuanyin Bio was founded in 2021.
Yuanyin Bio operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on RNA technology, circular RNA, innovative drugs and therapeutic solutions. Its customers include Healthcare providers, Pharmaceutical companies and Medical research institutions.
Yuanyin Bio has a B2B, Platform and B2B2C business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Yuanyin Bio has completed 3 funding rounds, raising a total of $142.00M. The latest funding stage is Series A.
Yuanyin Bio offers: Development of new pharmaceutical products, Research and application of circular RNA technology, Creation of therapeutic and preventive medicines.
Top alternatives and competitors to Yuanyin Bio include Cosmo Pharmaceuticals, MediciNova, Aclipse Therapeutics, Cirius Therapeutics, Orna Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Yuanyin Bio and Cosmo Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Yuanyin Bio, https://bouncewatch.com/company/yuanyin-bio, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout